Scientific Summary: BaxHTN Phase 3 Trial – Baxdrostat for Uncontrolled Hypertension
Scientific Summary: BaxHTN Phase 3 Trial – Baxdrostat for Uncontrolled Hypertension
Highlighted by Medical News Media – To be presented at ESC Congress 2025.
Published: July 14, 2025
phase-3-results.
Key Findings:
1. Study Design:
The BaxHTN trial was a phase 3, randomized, double-blind, placebo-controlled, multicenter study involving 796 patients with uncontrolled or treatment-resistant hypertension.
2. Patient Population:
• Uncontrolled hypertension: patients on 2 antihypertensive agents.
• Resistant hypertension: patients on 3 or more antihypertensives, including a diuretic.
Participants were randomized in a 1:1:1 ratio to receive:
• Baxdrostat 2 mg
• Baxdrostat 1 mg
• Placebo
3. Primary Outcome:
• Baxdrostat at both doses (1 mg and 2 mg) significantly reduced mean seated systolic blood pressure (SBP) compared to placebo at 12 weeks.
4. Secondary Endpoints:
• All secondary endpoints were met, showing robust efficacy across multiple BP measures.
5. Safety:
• Baxdrostat demonstrated a favorable safety profile throughout the 12-week study period.
https://www.astrazeneca.com/
